Guardant Health (GH) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.29

Estimate

-$0.31

Surprise

+7.8%

Revenue (period 2026-09-30)

$361.0M

Score today

5.6/10

Revenue source: xbrl.

Guardant Health (GH) reported a narrower loss than forecast — adjusted EPS of -$0.29 against the -$0.31 estimate (a 7.8% beat on a still-unprofitable quarter).

• Guardant Health Reports Q3 2026 Financial Results and Raises Full-Year Revenue Guidance — fiscal.ai, 2026-11-05
• Guardant Health Q3 2026 Earnings Call Transcript — benzinga, 2026-11-05
• Guardant Health Raises FY2026 Sales Guidance from $1.340B-$1.360B to $1.360B-$1.370B vs $1.357B Est — benzinga, 2026-11-05

TrendMatrix currently rates GH Hold at 5.6/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +7.8% surprise compares with a -0.4% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$148.14

Price target

$182.02

Stop

$137.77

Upside to target

+22.9%

Reward-to-risk

1.6:1

Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Diagnostics & Research

Market cap

$20.59B

P/E (fwd)

-404.6

52-week range

$74.55–$191.05

Off 52-week high

22.5%

RSI (14)

44

Volume vs avg

1.44×

Score today

5.6/10